Dosimetric assessment of prostate cancer patients through principal component analysis (PCA)

Journal of Applied Clinical Medical Physics

Volumn 14, Issue 1, 2013, Pages 40-49

  Gloi, Aime M ^a   Buchanan, Robert ^b  

^a St Vincent Hospital Green Bay   (United States)

^b Southeast Alabama Medical Center   (United States)

Author keywords

EUD; Exact logistic regression; NTCP; Principal component analysis; TCP

Indexed keywords

EID: 84873549526     PISSN: None     EISSN: 15269914     Source Type: Journal    
DOI: 10.1120/jacmp.v14i1.3882     Document Type: Article

References (31)

1. Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res. 2007;175:1-8.
2. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1998;41(1):83-92.
3. Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 2001;49(3):685-98.
4. Rancati T, Fiorino C, Gagliardi G, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol. 2004;73(1):21-32.
5. Sohn M, Yan D, Liang J, Meldolesi E, Vargas C, Alber M. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys. 2007;67(4):1066-73.
6. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47(1):103-13.
7. Tucker SL, Cheung R, Dong L, et al. Dose-volume response analysis of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59(2):353-65.
8. Vargas C, Martinez A, Kestin LL, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(5):1297-308.
9. Zapatero A, Garcia-Vicente F, Modolell I, et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys. 2004;59(5):1343-51.
10. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997;24(1):103-10.
11. Niemierko A. A generalized concept of equivalent uniform dose [abstract]. Med Phys. 1999;26:1100.
12. Dawson LA, Biersack M, Lockwood G, Eisbruch A, Lawrence TS, TenHaken RK. Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys. 2005;62(3):829-37.
13. Bauer JD, Jackson A, Skwarchuk M, et al. Principal component analysis as applied to volume effects in treatment outcomes for patients with prostate cancer treated with 3D-CRT [abstract]. Med Phys. 2004;31:1910.
14. Bauer JD, Jackson A, Skwarchuk M, Zelefsky M. Principal component, Varimax rotation and cost analysis of volume effects in rectal bleeding in patients treated with 3D-CRT for prostate cancer. Phys Med Biol. 2006;51(20):5105-23.
15. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using comformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(2):316-27.
16. Martinez AA, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and case specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169(3):974-79.
17. Vargas C, Martinez A, Galalae R, et al. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis. 2006;9(3):245-53.
18. Kestin LL, Martinez AA, Stromberg JS, et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol. 2000;18(15):2869-80.
19. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvis radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56(5):1354-60.
20. Fawzy EE, Moftah B, Eltaher Z, Beddo S. Small bowel toxicity in rectal cancer patients receiving concomitant pelvic irradiation and 5-Fluorouacil chemotherapy: is there any correlation with dose volume parameters? Sci Med J ESCME. 2004;16(1):1-16.
21. Devisetty K, Mell LK, Salama JK, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009;93(2):298-301.
22. Uzan J and Nahum AE. Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite. Br J Radiol. 2012;85(1017):1279-86.
23. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50(4):1021-31.
24. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;55(1):194-203.
25. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21(1):123-35.
26. Stavreva N Stavrev P, Warkentin B, Fallone BG. Derivation of the expressions for gamma50 and D50 for different individual TCP and NTCP models. Phys Med Biol. 2002;47(20):3591-604.
27. Jolliffe IT. Principal component analysis, 2nd edition. Springer Series in Statistics. New York: Springer; 2002.
28. Li XA, Wang JZ, Stewart RD, Dibiase SJ, Wang D, Lawton CA. Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. Br J Radiol. 2008;81(961):59-68.
29. Wang JZ, Li A, Yu CX, DiBiase SJ. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys. 2003;57(4):1101-08.
30. Tiong A, Bydder S, Ebert M, et al. A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys. 2010;76(4):1066-72.
31. Liang Y, Messer K, Brent SR, et al. Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data. Int J Radiat Oncol Biol Phys. 2010;78(3):912-19.